Search

Displaying results 1641 - 1650 of 1901 in total
  1. Drug

    Sacubitril

    go.drugbank.com/drugs/DB09292
    ApprovedInvestigational

    It was approved by the FDA after being given the status of priority review for on July 7, 2015.

  2. Drug

    Povidone

    go.drugbank.com/drugs/DB11061
    ApprovedInvestigationalWithdrawn

    The FDA withdrew its approval for the use of all intravenous drug products containing povidone.[L43942] Other formulations of povidone continue to be available.

  3. Drug

    Carbamide peroxide

    go.drugbank.com/drugs/DB11129
    ApprovedInvestigational

    The FDA considers carbamide peroxide to be safe in oral mucosal injury drug products as an oral wound healing agent, although there is insufficient data to establish general recognition of the effectiveness

  4. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    [L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1).

    Categories: Programmed Death Receptor-1 Blocking Antibody
  5. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    [T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition

  6. Drug

    Givosiran

    go.drugbank.com/drugs/DB15066
    Approved

    [A187991] Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [patisiran]), a new class of drugs promising an important and exciting step forward in the treatment

  7. Drug

    Islatravir

    go.drugbank.com/drugs/DB15653
    ApprovedInvestigational

    [A275492] On April 21, 2026, the FDA approved the first fixed-dose combination containing islatravir (0.25 mg) and the NNRTI doravirine (100 mg), marketed as IDVYNSO, as a complete once-daily regimen for

  8. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    [A253687] It was subsequently approved by the FDA in November 2024.[L51898,L51893]

  9. Drug

    Anacaulase

    go.drugbank.com/drugs/DB17449
    ApprovedInvestigational

    [A256047,A256052,A256057] The EMA approved the use of anacaulase in 2013,[A256047,A256052] and in January 2023, anacaulase received FDA approval.[L44717]

  10. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    [L56136] On April 23, 2026, the FDA granted accelerated approval for the treatment of pediatric and adult patients with severe-to-profound hearing loss associated with molecularly confirmed biallelic